MedDataX Logo

The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected Patients

NCT ID: NCT00001070

Last Updated: 2023-04-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to evaluate the tolerance and antiviral effect of oral vitamin C in HIV-infected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

NCT01944371

HIV Human Immunodeficiency Virus
COMPLETED PHASE1/PHASE2

A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

NCT00000792

HIV Infections
COMPLETED PHASE1

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591

HIV Infections
COMPLETED PHASE1

An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients

NCT00000650

HIV Infections
COMPLETED NA

A Study of CI-1012 in HIV-Infected Patients

NCT00002196

HIV Infections
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Vitamin C

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Not applicable - Study withdrawn since 04/23/1996
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role lead

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DATRI 017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
NCT00361101 COMPLETED PHASE1
Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
NCT05224492 UNKNOWN PHASE4
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
NCT02206711 COMPLETED PHASE1
Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon
NCT00658346 COMPLETED
A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects
NCT00397566 WITHDRAWN PHASE2
Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects
NCT00000740 COMPLETED PHASE1
A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides
NCT00389311 COMPLETED EARLY_PHASE1
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
NCT06045507 COMPLETED PHASE2
An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial (MTN-003)
NCT02358616 COMPLETED
Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol
NCT03517358 COMPLETED PHASE3
A Study of Lobucavir in Patients With AIDS
NCT00002352 COMPLETED NA
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
NCT00000823 COMPLETED PHASE2
A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body
NCT01045317 COMPLETED PHASE1
A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection
NCT01064752 COMPLETED
A Study of DPC 817 in HIV-Infected Males
NCT00040274 COMPLETED PHASE1
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
NCT00000657 COMPLETED PHASE2
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
NCT00000710 COMPLETED PHASE1
The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex
NCT00001011 COMPLETED PHASE3
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
NCT03570918 COMPLETED PHASE1
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
NCT00002097 COMPLETED PHASE1
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
NCT03407105 COMPLETED PHASE1
A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides
NCT00002114 COMPLETED PHASE2
Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
NCT00000643 COMPLETED PHASE2
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
NCT00001024 COMPLETED NA
Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults
NCT03408899 COMPLETED PHASE1